Search

ProQR management will host an investor conference call and webcast to discuss the Company’s Axiomer RNA editing technology platform following the recently announced partnership with Lilly. 

With the announcement of the expansion of ProQR and Lilly's partnership, ProQR Management is hosting a conference call.

On March 29, 2023 ProQR will host a virtual R&D event to showcase its proprietary Axiomer RNA-editing technology platform. ProQR will also announce initial pipeline targets for internal development.

During this webcast ProQR leadership will highlight key advancements from its clinical-stage pipeline and Axiomer® RNA editing platform.

ProQR Presentation at RNA Leaders Europe Congress

ProQR presentation and panel session at the Oligonucleotide and Precision Therapeutics (OPT) Congress

ProQR Presentation at the RNA Editing Gordon Research Conference (GRC)

ProQR shared additional analyses from the Phase 2/3 Illuminate trial of sepofarsen for LCA10 and provided an update on the company strategy. Management to host a conference call today at 8:00am EDT (14:00 CET).

ProQR will present new preclinical data for Axiomer, including the first preclinical data for its AX-0810 pipeline program for cholestatic diseases targeting NTCP at the ASGCT Annual Meeting, May 7-11, 2024, in Baltimore, Maryland.

ProQR will host a virtual Analyst and Investor Event on Wednesday, December 11, 2024 from 10:00 am until approximately 12:30 pm EST, including an Analyst Q&A session with members of the ProQR Management Team.